L. C. França

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

In-vitro Tests Suitability in Severe Systemic Reaction due to Several Drugs

B. D. L. H. Caballer, M. Sanz, R. Gijón, 2014 .

Passive assessment of tapping speed through smartphone is useful for monitoring multiple sclerosis.

E. Monreal, J. L. Chico-García, Fernando Rodríguez-Jorge, 2024, Multiple sclerosis and related disorders.